IP Library Granted Patent US 9,029,140
Granted Patent B2
US 9,029,140 · App. 13/036,569 · Granted May 12, 2015

Cell suspension preparation technique and device

Inventors: Fiona M. Wood (City Beach, AU); Marie L. Stoner (Maida Vale, AU)
Assignee: Avita Medical Limited
A61F2/105C12N5/0629C12N2500/99C12N2509/00A61K35/36C12M45/02C12M45/06C12M45/22C12M47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,029,140
App. No.
13/036,569
Granted
May 12, 2015
Kind
B2
Abstract

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.

Claims (45)

1. A method for preparing a cell suspension for direct application to a patient in need of a treatment for a skin disorder or disease, which method comprises the steps of:

(a) subjecting a donor skin tissue sample comprising a dermis layer and an epidermis layer to a dissociating means comprising an enzyme to dissociate the dermis layer and the epidermis layer at a dermal-epidermal junction in the skin tissue sample, wherein the donor skin tissue sample provides an expansion ratio of 1:10 to 1:80 in the treatment;

(b) removing the donor skin tissue sample from the dissociating means used in step (a) and immersing the donor skin tissue sample in a reservoir of nutrient solution, wherein the nutrient solution is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of the cells until applied to the patient and (iii) suitable for direct application to a recipient region on the patient;

(c) harvesting cells from a dermal surface facing the dermal-epidermal junction and an epidermal surface facing the dermal-epidermal junction in the reservoir of nutrient solution and suspending the harvested cells by mixing with the nutrient solution, thereby to produce a mixed suspension of dermal and epidermal cells in the reservoir of nutrient solution, wherein the harvested cells are suitable for grafting onto the patient and include keratinocyte basal cells, melanocytes and fibroblasts; and

(d) filtering the mixed suspension of dermal and epidermal cells from step (c) to remove cellular conglomerates greater than 200 μm, thereby producing a mixed cell suspension in the nutrient solution that is directly applied to the patient;

wherein the method does not comprise the steps of pelleting and resuspending the cells.

2. The method according to claim 1 wherein the enzyme is trypsin or trypsin-EDTA.

3. The method according to claim 1 wherein the enzyme is selected from the group consisting of dispase, collagenase, thermolysin, pronase, hyaluronidase, pancreatin, elastase and papain.

4. The method according to claim 1 wherein the skin tissue sample is subjected to the dissociating means for about 5 minutes to about 60 minutes.

5. The method according to claim 1 wherein the skin tissue sample is subjected to the dissociating means for about 15 minutes to about 20 minutes.

6. The method according to claim 1 wherein the nutrient solution is Hartmann's solution.

7. A method of treating a skin disorder or disease in a patient in need thereof, said method comprising the steps of:

(a) preparing the mixed cell suspension according to the method of claim 1 peri-operatively; and

(b) immediately administering the mixed cell suspension directly to the recipient region after said preparing step on the patient and without in vitro culturing.

8. A method for preparing a cellular suspension to provide a therapeutic preparation for direct application in a treatment of a skin disorder or disease, said method comprising:

(a) subjecting a donor skin tissue sample comprising a dermis layer and an epidermis layer to an enzyme to dissociate cohesive bonding between the dermis layer and the epidermis layer in the donor skin tissue sample, wherein the donor skin tissue sample provides an expansion ratio of 1:10 to 1:80 in the treatment;

(b) removing the donor skin tissue sample from a solution having the enzyme used in step (a) and immersing the skin tissue sample in a reservoir of nutrient solution, wherein the nutrient solution is (i) free of serum xenogenic to the patient, (ii) capable of maintaining viability of the cells until applied to the patient and (iii) suitable for direct application to a recipient region on the patient;

(c) harvesting cells from a dermal surface facing the dermal-epidermal junction and an epidermal surface facing the dermal-epidermal junction in the reservoir of nutrient solution and suspending the harvested cells by mixing with the nutrient solution, thereby to produce a mixed suspension of dermal and epidermal cells in the reservoir of nutrient solution, wherein the harvested cells are suitable for grafting onto the patient and include keratinocyte basal cells, melanocytes and fibroblasts; and

(d) filtering the mixed suspension of dermal and epidermal cells from step (c) to remove cellular conglomerates greater than 200 μm;

thereby producing a cellular suspension in the nutrient solution to provide a therapeutic preparation that is directly applied in the treatment of the skin disorder or disease.

9. The method according to claim 8 wherein the nutrient solution is Hartmann's solution.

10. The method according to claim 8 wherein the enzyme is selected from the group consisting of trypsin, trypsin-EDTA, dispase, collagenase, thermolysin, pronase, hyaluronidase, pancreatin, elastase and papain.

11. A method of treating a skin disorder or disease in a patient in need thereof, said method comprising the steps of:

(a) preparing the cellular suspension according to the method of claim 8 peri-operatively; and

(b) immediately administering the cellular suspension directly to the recipient region after said preparing step on the patient in need of treatment and without in vitro culturing.

12. The method of claim 1 , wherein the recipient region is receiving cell grafting.

13. The method of claim 1 , wherein the recipient region is receiving skin grafting.

14. The method of claim 8 , wherein the recipient region is receiving cell grafting.

15. The method of claim 8 , wherein the recipient region is receiving skin grafting.

16. A method for producing a mixed suspension of dermal and epidermal cells, the method comprising:

(a) providing a donor skin tissue sample in a reservoir of nutrient solution, the donor skin tissue sample being obtained from a patient and comprising a dermis layer, an epidermis layer, and a dermal-epidermal junction therebetween, wherein the donor skin tissue sample provides an expansion ratio of 1:10 to 1:80 in a skin treatment;

(b) harvesting cells from a dermal surface facing the dermal-epidermal junction and an epidermal surface facing the dermal-epidermal junction in the reservoir of nutrient solution and suspending the harvested cells by mixing with the nutrient solution, thereby to produce a mixed suspension of dermal and epidermal cells in the reservoir of nutrient solution; wherein prior to harvesting, the donor skin tissue sample has been subject to trypsin treatment; and

(c) filtering the mixed suspension of dermal and epidermal cells to remove cellular conglomerates greater than 200 μm,

wherein the nutrient solution is free of serum xenogenic to the patient and capable of maintaining viability of the dermal and epidermal cells, and wherein the filtered cells are directly applied to the patient for the skin treatment.

17. The method for preparing a cell suspension according to claim 1 wherein the dissociating means dissociates the dermis layer and epidermis layer by disrupting or weakening cohesive bonding between the dermis layer and the epidermis layer.

18. The method for preparing a cell suspension according to claim 1 , wherein step (b) further comprising rinsing the donor skin tissue sample after removal from the dissociating means and prior to immersing the donor skin tissue sample in the reservoir of nutrient solution.

19. A method of treating a skin disorder or disease in a patient, said method comprising the steps of:

(a) preparing the mixed suspension of dermal and epidermal cells according to the method of claim 16 peri-operatively; and

(b) immediately administering the mixed suspension of dermal and epidermal cells directly to a recipient site after said preparing step on the patient in need of treatment and without in vitro culturing.

20. The method of claim 1 , wherein the nutrient solution is a physiological saline.

21. The method of claim 8 , wherein the nutrient solution is a physiological saline.

22. The method of claim 8 , wherein the nutrient solution is a physiological saline.

23. The method of claim 1 , wherein the donor skin tissue sample is up to 2 cm×2 cm in size.

24. The method of claim 8 , wherein the donor skin tissue sample is up to 2 cm×2 cm in size.

25. The method of claim 16 , wherein the donor skin tissue sample is up to 2 cm×2 cm in size.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Jan 14, 2026
From: ORCO IV LLC
To: AVITA MEDICAL AMERICAS, LLC
Reel/Frame 073473/0540 →
SECURITY INTEREST Recorded Jan 13, 2026
From: AVITA MEDICAL, INC.; AVITA MEDICAL AMERICAS, LLC
To: PERCEPTIVE CREDIT HOLDINGS V, LP
Reel/Frame 073458/0492 →
SECURITY INTEREST Recorded Apr 1, 2024
From: AVITA MEDICAL AMERICAS, LLC
To: ORCO IV LLC
Reel/Frame 066960/0144 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2024
From: ORCO IV LLC
To: AVITA MEDICAL PTY LIMITED
Reel/Frame 066960/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2024
From: AVITA MEDICAL PTY LTD.
To: AVITA MEDICAL AMERICAS, LLC
Reel/Frame 066953/0770 →
SECURITY INTEREST Recorded Dec 13, 2023
From: AVITA MEDICAL PTY LIMITED
To: ORCO IV LLC
Reel/Frame 065856/0614 →
CHANGE OF NAME Recorded Sep 13, 2021
From: AVITA MEDICAL LTD
To: AVITA MEDICAL PTY LIMITED
Reel/Frame 057497/0166 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME FROM "MCCOMB FOUNDATION, INC." TO "MCCOMB FOUNDATION INC" AND UPDATE "MARIE STONER" TO "MARIE L. STONER" PREVIOUSLY RECORDED ON REEL 026351 FRAME 0455. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 18, 2018
From: STONER, MARIE L.; WOOD, FIONA M.
To: MCCOMB FOUNDATION INC
Reel/Frame 047270/0680 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME FROM "THE MCCOMB FOUNDATION, INC." TO "MCCOMB FOUNDATION INC" AND PROPERTY DETAILS LISTED ON SCHEDULE A. PREVIOUSLY RECORDED ON REEL 027297 FRAME 0634. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 18, 2018
From: MCCOMB FOUNDATION INC
To: AVITA MEDICAL LTD
Reel/Frame 047270/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2011
From: THE MCCOMB FOUNDATION, INC.
To: AVITA MEDICAL LTD
Reel/Frame 027297/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2011
From: STONER, MARIE L.; WOOD, FIONA M.
To: MCCOMB FOUNDATION, INC.
Reel/Frame 026351/0455 →
Priority Claims (1)
AU PR2989 · Feb 7, 2001 · national
Continuity (3)
Continuation 10068299 · Feb 6, 2002
Provisional Application 60281527 · Apr 4, 2001
Related Publication 20110150848A1 · Jun 23, 2011